Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2011

Open Access 01-02-2011 | Research article

Expression of K2P5.1 potassium channels on CD4+T lymphocytes correlates with disease activity in rheumatoid arthritis patients

Authors: Stefan Bittner, Nicole Bobak, Martin Feuchtenberger, Alexander M Herrmann, Kerstin Göbel, Raimund W Kinne, Anker J Hansen, Thomas Budde, Christoph Kleinschnitz, Oliver Frey, Hans-Peter Tony, Heinz Wiendl, Sven G Meuth

Published in: Arthritis Research & Therapy | Issue 1/2011

Login to get access

Abstract

Introduction

CD4+ T cells express K2P5.1 (TWIK-related acid-sensitive potassium channel 2 (TASK2); KCNK5), a member of the two-pore domain potassium channel family, which has been shown to influence T cell effector functions. Recently, it was shown that K2P5.1 is upregulated upon (autoimmune) T cell stimulation. The aim of this study was to correlate expression levels of K2P5.1 on T cells from patients with rheumatoid arthritis (RA) to disease activity in these patients.

Methods

Expression levels of K2P5.1 were measured by RT-PCR in the peripheral blood of 58 patients with RA and correlated with disease activity parameters (C-reactive protein levels, erythrocyte sedimentation rates, disease activity score (DAS28) scores). Twenty patients undergoing therapy change were followed-up for six months. Additionally, synovial fluid and synovial biopsies were investigated for T lymphocytes expressing K2P5.1.

Results

K2P5.1 expression levels in CD4+ T cells show a strong correlation to DAS28 scores in RA patients. Similar correlations were found for serological inflammatory parameters (erythrocyte sedimentation rate, C-reactive protein). In addition, K2P5.1 expression levels of synovial fluid-derived T cells are higher compared to peripheral blood T cells. Prospective data in individual patients show a parallel behaviour of K2P5.1 expression to disease activity parameters during a longitudinal follow-up for six months.

Conclusions

Disease activity in RA patients correlates strongly with K2P5.1 expression levels in CD4+ T lymphocytes in the peripheral blood in cross-sectional as well as in longitudinal observations. Further studies are needed to investigate the exact pathophysiological mechanisms and to evaluate the possible use of K2P5.1 as a potential biomarker for disease activity and differential diagnosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference van Vollenhoven RF: Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol. 2009, 5: 531-541. 10.1038/nrrheum.2009.182.CrossRef van Vollenhoven RF: Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol. 2009, 5: 531-541. 10.1038/nrrheum.2009.182.CrossRef
2.
go back to reference Feuchtenberger M, Kneitz C, Roll P, Kleinert S, Tony HP: Sustained remission after combination therapy with rituximab and etanercept in two patients with rheumatoid arthritis after tnf failure: case report. Open Rheumatol J. 2009, 3: 9-13. 10.2174/1874312900903010009.CrossRef Feuchtenberger M, Kneitz C, Roll P, Kleinert S, Tony HP: Sustained remission after combination therapy with rituximab and etanercept in two patients with rheumatoid arthritis after tnf failure: case report. Open Rheumatol J. 2009, 3: 9-13. 10.2174/1874312900903010009.CrossRef
3.
go back to reference van Gestel AM, Haagsma CJ, van Riel PL: Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998, 41: 1845-1850. 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K.CrossRef van Gestel AM, Haagsma CJ, van Riel PL: Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998, 41: 1845-1850. 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K.CrossRef
4.
go back to reference Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PL: Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009, 68: 954-960. 10.1136/ard.2007.084459.CrossRef Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PL: Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009, 68: 954-960. 10.1136/ard.2007.084459.CrossRef
5.
go back to reference Bittner S, Meuth SG, Gobel K, Melzer N, Herrmann AM, Simon OJ, Weishaupt A, Budde T, Bayliss DA, Bendszus M, Wiendl H: TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. Brain. 2009, 132: 2501-2516. 10.1093/brain/awp163.CrossRef Bittner S, Meuth SG, Gobel K, Melzer N, Herrmann AM, Simon OJ, Weishaupt A, Budde T, Bayliss DA, Bendszus M, Wiendl H: TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. Brain. 2009, 132: 2501-2516. 10.1093/brain/awp163.CrossRef
6.
go back to reference Meuth SG, Bittner S, Meuth P, Simon OJ, Budde T, Wiendl H: TWIK-related acid-sensitive K+ channel 1 (TASK1) and TASK3 critically influence T lymphocyte effector functions. J Biol Chem. 2008, 283: 14559-14570. 10.1074/jbc.M800637200.CrossRef Meuth SG, Bittner S, Meuth P, Simon OJ, Budde T, Wiendl H: TWIK-related acid-sensitive K+ channel 1 (TASK1) and TASK3 critically influence T lymphocyte effector functions. J Biol Chem. 2008, 283: 14559-14570. 10.1074/jbc.M800637200.CrossRef
7.
go back to reference Bittner S, Bobak N, Herrmann AM, Göbel K, Meuth P, Höhn KG, Stenner MP, Budde T, Wiendl H, Meuth SG: Upregulation of K2P5.1 potassium channels in multiple sclerosis. Annals of Neurology. 2010, 68: 58-69. 10.1002/ana.22010.CrossRef Bittner S, Bobak N, Herrmann AM, Göbel K, Meuth P, Höhn KG, Stenner MP, Budde T, Wiendl H, Meuth SG: Upregulation of K2P5.1 potassium channels in multiple sclerosis. Annals of Neurology. 2010, 68: 58-69. 10.1002/ana.22010.CrossRef
8.
go back to reference Goronzy JJ, Weyand CM: Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res Ther. 2009, 11: 249.CrossRef Goronzy JJ, Weyand CM: Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res Ther. 2009, 11: 249.CrossRef
9.
go back to reference Maxwell L, Singh JA: Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev. 2009, CD007277-4 Maxwell L, Singh JA: Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev. 2009, CD007277-4
10.
go back to reference Dixon W, Massey F: Introduction to Statistical Analysis. 1969, New York: McGraw-Hill Companies Dixon W, Massey F: Introduction to Statistical Analysis. 1969, New York: McGraw-Hill Companies
11.
go back to reference Mima T, Nishimoto N: Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol. 2009, 21: 224-230. 10.1097/BOR.0b013e3283295fec.CrossRef Mima T, Nishimoto N: Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol. 2009, 21: 224-230. 10.1097/BOR.0b013e3283295fec.CrossRef
12.
go back to reference Funahashi K, Koyano S, Miura T, Hagiwara T, Okuda K, Matsubara T: Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Mod Rheumatol. 2009, 19: 507-512. 10.1007/s10165-009-0203-z.CrossRef Funahashi K, Koyano S, Miura T, Hagiwara T, Okuda K, Matsubara T: Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Mod Rheumatol. 2009, 19: 507-512. 10.1007/s10165-009-0203-z.CrossRef
13.
go back to reference Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, Genovese MC: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010, 69: 88-96. 10.1136/ard.2008.105197.CrossRef Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, Genovese MC: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010, 69: 88-96. 10.1136/ard.2008.105197.CrossRef
14.
go back to reference Matsui T, Komiya A, Shimada K, Nakayama H, Tohma S: Neutrophil CD64 as a marker of infection in patients treated with tocilizumab. Mod Rheumatol. 2009, 19: 696-697. 10.1007/s10165-009-0223-8.CrossRef Matsui T, Komiya A, Shimada K, Nakayama H, Tohma S: Neutrophil CD64 as a marker of infection in patients treated with tocilizumab. Mod Rheumatol. 2009, 19: 696-697. 10.1007/s10165-009-0223-8.CrossRef
Metadata
Title
Expression of K2P5.1 potassium channels on CD4+T lymphocytes correlates with disease activity in rheumatoid arthritis patients
Authors
Stefan Bittner
Nicole Bobak
Martin Feuchtenberger
Alexander M Herrmann
Kerstin Göbel
Raimund W Kinne
Anker J Hansen
Thomas Budde
Christoph Kleinschnitz
Oliver Frey
Hans-Peter Tony
Heinz Wiendl
Sven G Meuth
Publication date
01-02-2011
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2011
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3245

Other articles of this Issue 1/2011

Arthritis Research & Therapy 1/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.